New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 13, 2014
15:10 EDTMDT, EWMedtronic says CoreValve ruling has no impact outside U.S.
The Federal District Court of Delaware granted in part Edwards Lifesciences' (EW) motion for a preliminary injunction that prevents Medtronic (MDT) from selling or offering to sell its CoreValve System in the United States. The ruling has no impact on the sale or marketing of CoreValve outside of the United States or the use of CoreValve in the current U.S. clinical trials. At Medtronic's request, the Federal District Court agreed to postpone the implementation of the order for seven business days to allow Medtronic to seek prompt relief from the Federal Circuit Court of Appeals. Medtronic is appealing the court's injunction, and intends to ask the Federal Circuit Court of Appeals to prevent it from going into effect until it determines if the injunction was properly issued. In addition, the court ordered Medtronic and Edwards Lifesciences to enter into discussions immediately to agree on a mechanism that will enable physicians at facilities currently trained on CoreValve to make a clinical judgment as to which device to implant, CoreValve or the Edwards device, free from the limitations of the injunction. The court stated that CoreValve is a 'safer device, and that patients in whom it is implanted have better outcomes with a lower risk of death.' The court also found that the public interest favors enforcement of patent rights. The CoreValve System received approval from the FDA in January for patients at extreme risk for surgical valve replacement. Prior to that date, CoreValve therapy was available to extreme risk patients who were eligible to participate in the U.S. clinical trial.
News For MDT;EW From The Last 14 Days
Check below for free stories on MDT;EW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
17:12 EDTEWOn The Fly: Closing Wrap
Subscribe for More Information
08:16 EDTEWEdwards Lifesciences price target raised to $103 from $96 at Canaccord
Subscribe for More Information
July 29, 2014
18:35 EDTEWOn The Fly: After Hours Movers
Subscribe for More Information
16:18 EDTEWEdwards Lifesciences sees Q3 EPS 66c-72c, consensus 74c
Subscribe for More Information
16:17 EDTEWEdwards Lifesciences raises 2014 EPS outlook to $3.24-$3.34, consensus $3.19
Subscribe for More Information
16:16 EDTEWEdwards Lifesciences reports Q2 EPS 88c, consensus 77c
Reports Q2 revenue $575.1M, consensus $544.3M.
15:53 EDTEWNotable companies reporting after market close
Subscribe for More Information
July 28, 2014
12:46 EDTMDTMedtronic receives FDA approval for PRESTIGE cervical disc system
Subscribe for More Information
11:07 EDTEW, MDTLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
06:52 EDTMDTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
July 25, 2014
06:30 EDTMDTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
08:19 EDTMDTLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
July 22, 2014
07:57 EDTEWHouse Energy & Commerce Committee to hold a hearing
The Subcommittee on Health holds a hearing entitled, "21st Century Cures: Examining Barriers to Ongoing Evidence Development and Communication" with CEO Mussallem at Edwards Lifesciences on July 22 at 3 pm. Webcast Link
July 21, 2014
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use